SLV 332

Drug Profile

SLV 332

Alternative Names: Neurokinin 2 antagonist - Solvay; NK-2 antagonist - Solvay; SLV-332

Latest Information Update: 11 Jul 2007

Price : $50

At a glance

  • Originator ArQule
  • Class Irritable bowel syndrome therapies
  • Mechanism of Action Neurokinin 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 11 Jul 2007 Discontinued - Preclinical for Irritable bowel syndrome in Europe (unspecified route)
  • 29 Sep 2006 Data presented at the 232nd American Chemical Society National Meeting (232nd-ASC-2006) have been added to the Digestive System Disorders pharmacodynamics section
  • 01 Sep 2005 SLV 332 is still in active development - BIO-2005 Annual International Convention (BIO-2005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top